KR
Telix Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Illuccix® (TLX591-CDx) | Prostate Cancer Imaging (PSMA-PET) | Approved |
| Gozellix® | Not Specified (Diagnostic) | Not Specified |
| TLX591 (177Lu) | Prostate Cancer Therapy | Phase III |
| TLX101-CDx (Pixclara®) | Brain Cancer (Glioma) Imaging | Pre-NDA/Phase III |
| TLX101 (131I) | Brain Cancer (Glioma) Therapy | Phase I/II |
| TLX250-CDx (89Zr) | Kidney Cancer (Clear Cell RCC) Imaging | Phase III |
| TLX250 (177Lu) | Kidney Cancer (Clear Cell RCC) Therapy | Phase I |
| TLX301 (177Lu) | Sarcoma & Other Solid Tumors | Phase I |
Leadership Team at Telix Pharmaceuticals
MN
Mark Nelson
Non-Executive Director and Chair (Interim)
DC
Dr. Christian Behrenbruch
Managing Director & Group Chief Executive Officer
MM
Marie McDonald
Independent Non-Executive Director
JS
Jann Skinner
Independent Non-Executive Director
GR
Genevieve Ryan
Company Secretary
DS
Darren Smith
Group Chief Financial Officer
DD
Dr. David Cade
Group Chief Medical Officer
MJ
Mary Jessel
Group Chief of Clinical Affairs
CK
Christian Krautkramer
Group General Counsel
RV
Richard Valeix
Chief Executive Officer, Telix Therapeutics